The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.
Bibliographical noteFunding Information:
MKH has received research funds (grants paid to the institution) from Pfizer, Eli Lilly, Aclaris, and the National Alopecia Areata Foundation.
This article is published as part of a supplement sponsored by the National Alopecia Areata Foundation .
Funding for the Summit and publication of this supplement was provided by the National Alopecia Areata Foundation. This Summit was supported (in part) by the National Institute of Arthritis and Musculoskeletal and Skin Diseases under Award Number R13AR074890. The opinions or views expressed in this professional supplement are those of the authors and do not necessarily reflect the official views, opinions, or recommendations of the National Institutes of Health or the National Alopecia Areata Foundation.
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural